Topical and intravenous administration of human umbilical cord mesenchymal stem cell in patients with diabetic foot ulcer: A pilot study

The safety and efficacy of human umbilical cord mesenchymal stem cell administration in patients with diabetic foot ulcer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200055885

Enrollment

Unknown

Registered

2022-01-22

Start date

2009-09-15

Completion date

Unknown

Last updated

2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic foot ulcer

Interventions

hUC-MSC treatment group:hUC-MSC infusion+supporting treatment

Eligibility

Sex/Gender

All

Age

39 Years to 76 Years

Inclusion criteria

Inclusion criteria: 1.Diagnosed with type 2 diabetes according to the World Health Organization (WHO) guideline; 2.Aged 18 to 80 years; 3.Wagner grade >= 1; 4.Lower-limb unhealing ulcer after 6 weeks of routine treatments.

Exclusion criteria

Exclusion criteria: 1.Known allergy to stem cell or its derivant product or vehicle; 2.Serious cardiovascular, pulmonary, or liver dysfunction; 3.Uncontrolled immunological disease or active serious systemic infection; 4.Malignancy history.

Design outcomes

Primary

Measure	Time frame
Wagner grade;DFU healing rate;	—

Secondary

Measure	Time frame
DFU recurrence rate;	—

Countries

China

Contacts

Public ContactZhang Che

Affiliated Taihe Hospital of Hubei University of Medicine

prof.zh@163.com+86 719 8801691

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026